Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved publishing date : 2020 - 12 - 21 save search
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital MarketTrading on Nasdaq Capital Market is expected to begin on December 23, 2020
Published: 2020-12-21 (Crawled : 00:00) - biospace.com/
ITRM | $1.43 -0.69% 60K
|
Health Technology
|
| O: -0.11%
H: 11.86%
C: 9.28%
approval nasdaq
Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations
Published: 2020-12-21 (Crawled : 00:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: -1.56%
H: 1.1%
C: 0.66%
fda approval fda approval rare
PropTech Acquisition Corp. Stockholders Overwhelmingly Approve Business Combination with Porch.com; Cash Proceeds to Exceed $322 Million Following Transaction Closing
Published: 2020-12-21 (Crawled : 23:00) - globenewswire.com
PRCH 4 | $3.26 1.24% 1.23% 1M
|
Information
|
| O: 7.65%
H: 11.65%
C: 9.82%
acquisition acquisition corp
Eaton Vance Floating-Rate Income Plus Fund Announces Board Approval of New Investment Advisory Agreement
Published: 2020-12-21 (Crawled : 22:07) - prnewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.62%
H: 0.0%
C: -2.36%
approval
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Published: 2020-12-21 (Crawled : 22:03) - globenewswire.com
ITRM | $1.43 -0.69% 60K
|
Health Technology
|
| O: 5.42%
H: 4.85%
C: 0.97%
approval therapeutics nasdaq
Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
Published: 2020-12-21 (Crawled : 15:00) - biospace.com/
TSHA | $2.265 -6.02% -6.4% 1.8M
|
Health Technology
|
| O: -0.94%
H: 2.89%
C: -0.05%
approval therapy gene therapies trial phase 3 phase 1 phase 2 gene therapy tsha-102
Strategic combination plan receives all key regulatory approvals
Published: 2020-12-21 (Crawled : 14:00) - globenewswire.com
CVE | $20.85 0.92% -0.82% 6.4M
|
Energy Minerals
|
| O: -6.41%
H: 4.41%
C: 3.24%
approval
Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2020-12-21 (Crawled : 14:00) - biospace.com/
LEGN | $46.14 -2.08% -2.12% 1.2M
|
Health Technology
|
| O: -2.15%
H: 2.64%
C: -0.7%
fda approval biotech license therapy car-t submission cel
CVR Energy Announces Full Board Approval for Wynnewood Renewable Diesel Unit Project
Published: 2020-12-21 (Crawled : 13:03) - globenewswire.com
CVI | $32.82 0.83% 0.0% 680K
|
Energy Minerals
|
| O: -4.65%
H: 2.12%
C: 0.14%
approval renewable energy
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
Published: 2020-12-21 (Crawled : 12:03) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 2.43%
H: 3.76%
C: -7.52%
approval treatment libmeldy
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
Published: 2020-12-21 (Crawled : 00:12) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 2.67%
H: 1.3%
C: -3.25%
fda approval fda approval therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.